文献速递认知障碍与痴呆

临床前阿尔茨海默病中血浆p-tau217、tau PET与认知的同步变化

Concurrent Changes in Plasma Phosphorylated Tau 217, Tau PET, and Cognition in Preclinical Alzheimer Disease.
PubMed 文献 · JAMA Neurol · 2025-01-01

本研究基于A4与LEARN研究1707名认知未受损老年人,评估血浆p-tau217与tau PET在追踪临床前阿尔茨海默病进展中的价值。发现tau PET在额顶叶区域的变化与同步认知变化强相关,血浆p-tau217可预测认知变化并指导受试者选择。

要点

  • 血浆p-tau217可预测临床前AD的认知变化,并高效指导试验受试者选择。
  • tau PET在额顶叶区域的变化与同步认知变化强相关,适用于实时追踪疾病进展。
  • 基线内嗅皮层tau PET与血浆p-tau217对Aβ+者PACC变化预测最强。

核心结论

  • tau PET对预后评估和实时追踪疾病进展均有价值。
  • 血浆p-tau217可预测显性认知损害前的认知变化,并能高效指导受试者选择。
  • 基于影像的tau指标可能增强未来AD试验中疾病修饰效应的检测并优化治疗靶点。

研究设计与样本

  • 诊断/预后研究,使用A4研究2014年4月至2023年6月的纵向数据。
  • 纳入美国、加拿大、澳大利亚和日本67个中心的65-85岁认知未受损且接受淀粉样蛋白PET的老年人。
  • A4研究纳入1169名Aβ+者,LEARN研究纳入538名无淀粉样蛋白PET升高者,共1707人。
  • tau PET子研究纳入443人,血浆p-tau217数据来自1643人。

主要发现

  • Aβ+者36个月时tau PET累积效应最大的区域为颞下回。
  • Aβ+者基线内嗅皮层tau PET与PACC纵向变化相关性ρ=-0.55(95%CI -0.63至-0.45)。
  • Aβ+者基线血浆p-tau217与PACC纵向变化相关性ρ=-0.47(95%CI -0.56至-0.37)。
  • 额顶叶区域tau PET变化与同步认知变化强相关。
  • Aβ+者血浆p-tau217显著升高后出现显著减速(χ2=21.7;P<.001)。

关键数值与推荐

  • Aβ+定义:18F-florbetapir PET显示淀粉样蛋白β升高。
  • tau测量:纵向血浆p-tau217和18F-flortaucipir PET。
  • 认知评估:临床前阿尔茨海默认知复合量表(PACC)。

临床怎么用

  • 血浆p-tau217可用于临床前AD试验的受试者筛选和认知变化预测。
  • tau PET可用于实时追踪疾病进展并评估疾病修饰治疗效果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Developing disease-modifying treatments is a priority for Alzheimer disease research. OBJECTIVE: To determine the potential of plasma phosphorylated tau 217 (p-tau217) and tau positron emission tomography (PET) to assess disease modification in treatment trials. DESIGN, SETTING, AND PARTICIPANTS: This diagnostic/prognostic study used longitudinal data from the Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) study collected from April 2014 to June 2023. Recruited from 67 sites in the US, Canada, Australia, and Japan, participants included older individuals (age 65-85 years) who were cognitively unimpaired at screening and underwent an amyloid PET scan. Participants without elevated amyloid PET were included from a companion to the A4 study, the Longitudinal Evaluation of Amyloid Risk and Neurodegeneration (LEARN) study. EXPOSURE: 18F-florbetapir PET imaging. MAIN OUTCOMES AND MEASURES: 18F-florbetapir PET imaging was used to classify participants as having elevated amyloid β (Aβ+). Measures of tau included longitudinal plasma p-tau217 and 18F-flortaucipir PET. Cognition was assessed using the Preclinical Alzheimer Cognitive Composite (PACC). RESULTS: A total of 1169 individuals were included from A4 Study and 538 without elevated amyloid PET were included from the LEARN Study. Among these 1707 participants, the baseline mean (SD) age was 71.5 (4.7) years, 1024 (60%) were female, and 683 (40%) male; 1169 participants were Aβ+, and the mean (SD) Mini-Mental State Examination score was 28.8 (1.2). The tau PET substudy included 443 participants; plasma p-tau217 levels were available for 1643 participants. The largest effect size of longitudinal tau PET accumulation at 36 months in Aβ+ participants was in the inferior temporal gyrus. Baseline associations with longitudinal change in PACC score in Aβ+ participants were strongest in the entorhinal cortex (correlation [ρ] = -0.55; 95% CI, -0.63 to -0.45) and plasma p-tau217 levels (ρ = -0.47; 95% CI, -0.56 to -0.37). Tau PET changes in frontoparietal regions were strongly correlated with concurrent cognitive changes. Levels of plasma p-tau217 increased significantly in Aβ+ participants before showing significant deceleration (χ2 = 21.7; P < .001) and were not associated with concurrent cognitive change in the tau PET substudy (ρ = -0.03; 95% CI, -0.23 to 0.16) but were modestly associated with concurrent cognitive changes in the full plasma sample (n = 1119; ρ = -0.24; 95% CI, -0.34 to -0.14). CONCLUSIONS AND RELEVANCE: This study found that tau PET is valuable for both prognostic and real-time tracking of disease progression. Plasma p-tau217 predicts cognitive changes prior to overt cognitive impairment and can efficiently guide participant selection. Imaging-based tau measures may enhance detection of disease-modifying effects and refine therapeutic targets in future Alzheimer disease trials.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Insel PS, Mattsson-Carlgren N, Langford O, et al. Concurrent Changes in Plasma Phosphorylated Tau 217, Tau PET, and Cognition in Preclinical Alzheimer Disease. JAMA Neurol. 2025. PMID: 40853684. doi:10.1001/jamaneurol.2025.2974

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。